Béguin S, Kumar R, Keularts I, Seligsohn U, Coller B S, Hemker H C
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM) and Medical Faculty University of Maastricht, Maastricht, The Netherlands.
Blood. 1999 Jan 15;93(2):564-70.
Thrombin generation in platelet-rich plasma (PRP) involves complex interactions between platelets and coagulation proteins. We previously reported that the addition of fibrin to PRP enhances tissue-factor initiated thrombin generation by approximately 40%, and the current studies were designed to assess the mechanism(s) underlying thrombin generation in the absence and presence of fibrin. Blocking platelet GPIIb/IIIa + alphavbeta3 receptors with a monoclonal antibody (MoAb) inhibited basal thrombin generation, but did not affect the enhancement produced by fibrin. In contrast, blocking GPIb with any of three different MoAbs had no effect on basal thrombin generation, but essentially eliminated fibrin enhancement of thrombin generation. When thrombin generation was tested in PRP deficient in von Willebrand factor (vWF), both basal and fibrin-enhanced thrombin generation were markedly reduced, and the addition of factor VIII did not normalize thrombin generation. Botrocetin, which induces the binding of vWF to GPIb, enhanced thrombin generation. In all studies, the ability of PRP to support thrombin generation correlated with the production of platelet-derived microparticles and serum platelet-derived procoagulant activity. Thus, two separate mechanisms, both of which depend on vWF, appear to contribute to platelet-derived procoagulant activity: one is independent of fibrin and relies primarily on GPIIb/IIIa, but with a minor contribution from alphavbeta3; and the other is fibrin-dependent and relies on GPIb. These data may have implications for understanding the mechanisms of the abnormalities in serum prothrombin times reported in Bernard-Soulier syndrome, hemorrhage in von Willebrand disease (vWD), and the increased risk of thrombosis associated with elevated vWF levels.
富血小板血浆(PRP)中的凝血酶生成涉及血小板与凝血蛋白之间的复杂相互作用。我们之前报道,向PRP中添加纤维蛋白可使组织因子启动的凝血酶生成增强约40%,而当前研究旨在评估在不存在和存在纤维蛋白的情况下凝血酶生成的潜在机制。用单克隆抗体(MoAb)阻断血小板糖蛋白IIb/IIIa + αvβ3受体可抑制基础凝血酶生成,但不影响纤维蛋白产生的增强作用。相比之下,用三种不同的MoAb中的任何一种阻断糖蛋白Ib对基础凝血酶生成没有影响,但基本上消除了纤维蛋白对凝血酶生成的增强作用。当在缺乏血管性血友病因子(vWF)的PRP中测试凝血酶生成时,基础和纤维蛋白增强的凝血酶生成均显著降低,并且添加因子VIII并不能使凝血酶生成恢复正常。诱导vWF与糖蛋白Ib结合的蛇毒蛋白增强了凝血酶生成。在所有研究中,PRP支持凝血酶生成的能力与血小板衍生微粒的产生和血清血小板衍生促凝活性相关。因此,两种独立的机制似乎都有助于血小板衍生促凝活性,这两种机制均依赖于vWF:一种独立于纤维蛋白,主要依赖于糖蛋白IIb/IIIa,但αvβ3有较小贡献;另一种依赖于纤维蛋白,依赖于糖蛋白Ib。这些数据可能有助于理解伯纳德-索利尔综合征中报道的血清凝血酶原时间异常、血管性血友病(vWD)出血以及与vWF水平升高相关的血栓形成风险增加的机制。